Ghost Tree Capital’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Ghost Tree Capital’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-60,000	Closed	-$1.76M	–	54
2021 Q4	$1.76M	Buy	+60,000	New	+$1.86M	0.63%	41
2020 Q1	–	Sell	-33,400	Closed	-$2.65M	–	64
2019 Q4	$2.65M	Buy	+33,400	New	+$1.98M	0.51%	43
2019 Q3	–	Sell	-300,000	Closed	-$15.8M	–	52
2019 Q2	$15.8M	Hold	300,000	–	–	3.27%	10
2019 Q1	$15.9M	Buy	300,000 +200,000	+200%	+$9.83M	4.15%	6
2018 Q4	$4.11M	Buy	100,000 +88,000	+733%	+$3.3M	1.49%	23
2018 Q3	$456K	Sell	12,000 -230,000	-95%	-$10.2M	0.1%	54
2018 Q2	$10.9M	Buy	+242,000	New	+$11M	3.22%	9
2018 Q1	–	Sell	-325,000	Closed	-$12.8M	–	65
2017 Q4	$12.8M	Buy	325,000 +75,000	+30%	+$2.8M	3%	8
2017 Q3	$7.76M	Buy	+250,000	New	+$7.03M	1.65%	23

Other funds holding GBT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Ghost Tree Capital's GBT Position: Q1 2022 in Review

Ghost Tree Capital sold out of Global Blood Therapeutics, Inc. (GBT) in Q1 2022, closing a stake of 60,000 shares — an estimated $1.76M sold.

Ghost Tree Capital first reported a position in GBT in Q3 2017 and held it in 9 quarters. The position peaked at $15.9M in Q1 2019. 204 funds tracked by Wall St. Rank hold GBT as of Q1 2022.

Ghost Tree Capital reported no remaining Global Blood Therapeutics, Inc. position as of Q1 2022 after selling out during the quarter.
Ghost Tree Capital sold 60,000 Global Blood Therapeutics, Inc. shares in Q1 2022, an estimated $1.76M.
Ghost Tree Capital first reported a position in Global Blood Therapeutics, Inc. in Q3 2017 and held it in 9 quarters.
Ghost Tree Capital's Global Blood Therapeutics, Inc. position peaked at $15.9M in Q1 2019.
204 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q1 2022.

Based on Ghost Tree Capital's 13F filing for Q1 2022, filed 16 May 2022.